Inspire Medical Systems' stock experienced a significant pre-market plunge of 12.30%, indicating heavy selling pressure ahead of the trading session.

The sharp decline follows the company's release of its 2026 financial outlook, which fell short of analyst expectations. Inspire Medical Systems projected revenue between $950 million and $1 billion for the year, below the FactSet consensus estimate of $1.01 billion.

In response to the disappointing guidance, multiple Wall Street firms, including RBC, Jefferies, JP Morgan, and Leerink Partners, significantly reduced their price targets for the stock. The collective analyst downgrades amplified negative sentiment among investors, contributing to the pre-market selloff.